Trimarchi Thomas 4

What Happened

• Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma (BBIO), disposed a total of 32,419 shares in mid‑February 2026. On 2026-02-16, 18,819 shares were withheld to satisfy tax obligations related to the vesting of RSUs (18,819 shares withheld of 37,503 vested RSUs) at $75.25/share (value $1,416,130). On 2026-02-17, he sold 13,400 shares at $74.71 ($1,001,071) and 200 shares at $75.38 ($15,076) in open-market transactions effected under a pre-established 10b5-1 plan. Combined proceeds/value of these dispositions ≈ $2,432,277. These are dispositions (sales/withholding), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-16: 18,819 shares withheld for taxes at $75.25 (Disposition; $1,416,130)
  • 2026-02-17: 13,400 shares sold at $74.71 (Disposition; $1,001,071)
  • 2026-02-17: 200 shares sold at $75.38 (Disposition; $15,076)
• Total shares disposed: 32,419; total value ≈ $2.43M.
• Shares owned after the transactions: not specified in this Form 4 filing.
• Footnotes of note:
  • F1: 18,819 shares were withheld to satisfy tax on the vesting of 37,503 RSUs.
  • F2: The open-market sales were made under a Rule 10b5-1 plan adopted March 31, 2025.
  • F3: The filing states a weighted average sale-price range ($74.30–$75.19) and offers to provide a per-price breakdown upon request.
• Filing timing: Form 4 was filed on 2026-02-18 for transactions on 2026-02-16 and 02-17 (appears timely under standard Form 4 rules).

Context

• The 18,819-share disposition was a tax-withholding related to RSU vesting (routine administrative disposition), not a market sale intended to raise cash. The Feb 17 sales were executed under a pre-arranged 10b5-1 plan, which is a common way for insiders to sell shares according to a pre-set schedule. These transactions are disposals and do not indicate a purchase-based bullish signal.